SCHEDULE 13G/A 0001104659-25-078851 0001940272 XXXXXXXX LIVE 1 Common Stock, par value $0.00001 per share 12/31/2025 0001709941 BioAge Labs, Inc. 09077V100 5885 Hollis Street Suite 370 Emeryville CA 94608 Rule 13d-1(b) ADAR1 Capital Management, LLC b TX 0.00 135560.00 0.00 135560.00 135560.00 N 0.4 IA OO Includes (i) 104,666 shares of common stock, par value $0.00001 per share ("Common Stock") held by ADAR1 Partners, LP, and (ii) 15,275 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 15,619 shares of Common Stock held by other separately managed accounts as of December 31, 2025. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts. Based on 35,855,037 shares of Common Stock of BioAge Labs, Inc. (the "Issuer") outstanding as of October 31, 2025, reported in the Issuer's Form 10-Q for the quarterly period ended September 30, 2025, filed with the Securities and Exchange Commission on November 6, 2025. Daniel Schneeberger b V8 0.00 135560.00 0.00 135560.00 135560.00 N 0.4 HC IN Includes (i) 104,666 shares of common stock, par value $0.00001 per share ("Common Stock") held by ADAR1 Partners, LP, and (ii) 15,275 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 15,619 shares of Common Stock held by other separately managed accounts as of December 31, 2025. As the manager of ADAR1 Capital Management, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, and Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above. Based on 35,855,037 shares of Common Stock of BioAge Labs, Inc. (the "Issuer") outstanding as of October 31, 2025, reported in the Issuer's Form 10-Q for the quarterly period ended September 30, 2025, filed with the Securities and Exchange Commission on November 6, 2025. BioAge Labs, Inc. 5885 Hollis Street, Suite 370, Emeryville, CA 94608 This Schedule is being filed on behalf of each of the following persons (each, a "Reporting Person" and collectively, the "Reporting Persons"): (i) ADAR1 Capital Management, LLC ("ADAR1 Capital Management"); and (ii) Daniel Schneeberger ("Mr. Schneeberger"). The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738. (i) ADAR1 Capital Management is a Texas limited liability company; and (ii) Mr. Schneeberger is a citizen of Switzerland. N IA HC The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. The information contained on the cover pages of this Schedule 13G is incorporated herein by reference. N Y Y N Mr. Schneeberger is filing this Schedule 13G as a control person in respect of shares beneficially owned by ADAR1 Capital Management, an investment adviser as described in SS 240.13d-1(b)(1)(ii)(E). Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. ADAR1 Capital Management, LLC /s/ Daniel Schneeberger 02/17/2026 Daniel Schneeberger /s/ Daniel Schneeberger 02/17/2026